Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

NCT04825834 is registered in ClinicalTrials.gov with Delfi Diagnostics Inc. as lead sponsor.

NCT NCT04825834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04825834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
Lead sponsor
Delfi Diagnostics Inc.
Phase
Observational
Overall status
Completed
Start date
March 22, 2021
Completion date
July 15, 2025
Enrollment
2,992 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal cancer, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, pancreas cancer, skin cancer, stomach cancer